Viropro's Dr. Rajiv Datar to be Guest Speaker at SALSS

VIROPRO (PK: VPRO) announces Dr. Rajiv Datar will be a guest speaker at this year’s Swedish-American Life Sciences Summit in Stockholm, Sweden. The Summit will be held from August 24th to the 26th.

Dr. Datar, who holds a Ph. D. in Bioprocess Technology from the Royal Institute of Technology (KTH) of Stockholm, and a Post-Doctorate from MIT, Cambridge, MA, has been invited to present Viropro’s profile and business plan on August 26th to an attendance of executives of the Life Sciences Industry. Dr Datar comments:

“It will be an immense pleasure to get re-acquainted with the Swedish Life Sciences Community and to participate in this event, which will bring considerable attention to our efforts.”

ABOUT SALSS

The Swedish-American Life Science Summit 2011

The Swedish-American Life Science Summit 2011 is the seventh in a series of summits, in an invitation-only format where we present a program featuring some of the best known Life Science executives and investors in the world.

The intense and exclusive two-day program includes high-level panel discussions, insights from keynote speakers as well as a few selected presentations by successful and promising Swedish companies.

It is our hope and ambition that the summit will serve to increase the amount of cross-border business between the largest market in the world, the United States, and one of the most important Life Science industry centers in Europe, Sweden.

In addition, over the last couple of years the summit has taken on an increasingly global nature, making the summit a true reflection of the Life Science industry today.

About Viropro, Inc.:

Viropro, Inc. conducts operations through its subsidiaries Viropro International Inc., and Biologics Process Development, Inc. and specializes in the transfer of its technologies for industrial production of biopharmaceutical therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. The Company’s principal objective is to provide its high-yield manufacturing process technology to biopharmaceutical companies in global markets with unmet medical and/or market needs. (www.viropro.com)

Viropro Inc. Safe Harbor Statement

Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.